BeyondSpring receives FDA Fast Track designation for Plinabulin
BeyondSpring announced that the US FDA granted Fast Track designation to Plinabulin combined with docetaxel for treating advanced non-squamous non-small ce
BeyondSpring announced that the US FDA granted Fast Track designation to Plinabulin combined with docetaxel for treating advanced non-squamous non-small ce